us pipeline overview neurodegenerative diseases cns oncology solutions overview drug repositioning combination therapies drug de risking clinical hold for stakeholders biotech pharma companies generics companies patient advocacy groups technology research overview collaborative research publications news blog events press releases biovista articles media coverage announcements vizit blog follow us recent posts biovista patent for the use of tetracyclic pyrazinoindoles issued in the eu april 21 2016 extreme user profiling good or bad for search and scientific discovery april 20 2016 why systematic drug repurposing is here to stay february 4 2016 survey of therapeutic strategies for chronic fatigue syndrome february 2 2016 biovista inc. announces drug repositioning collaboration with astellas pharma december 4 2015 about us company our vision management team collaborations partnership program contact us pipeline overview neurodegenerative diseases cns oncology solutions overview drug repositioning combination therapies drug de risking clinical hold for stakeholders biotech pharma companies generics companies patient advocacy groups technology research overview collaborative research publications news blog events press releases biovista articles media coverage announcements vizit blog drug repositioning development combination therapies bva701 bva101 bva201 super generics lifecycle management differentiation cfs cns orphan diseases benefit risk mechanism of action profiling rare diseases discovery efficiency innovation oncology adverse events systematic patient groups personalized medicine clinical hold pipeline optimization epilepsy partnering with biopharma companies to deliver well differentiated innovative therapies a portfolio of licensing opportunities to address unmet medical needs bringing novel therapy options to patients with rare and orphan diseases drug repositioning we profile compounds whether in late development in the market or at the generic phase and match them with diseases to find new uses for drugs or new therapies for indications of interest more combination therapies we identify compounds to combine with a drug of interest and find novel combinations to address unmet medical needs or help differentiate from marketed and generic drugs more drug de risking we proactively assess the benefit risk profile of drugs to optimize population targeting improve clinical trial design and help manage unanticipated side effects before they arise more clinical hold we generate strong mechanism of action rationale and the supporting evidence to help you remove a clinical hold order and bring your drug development program back on track more pipeline biovista is developing therapies in multiple sclerosis mitochondrial diseases oncology epilepsy and cfs me . biovista candidates are repositioned drugs presently at the late pre clinical stage and following the fda 505 b 2 development route . additional repositioning work is being pursued in orphan rare diseases in collaboration with our partners . stakeholders biopharma companiesbiovista b2b services offer a proven and cost effective management tool to exploit or salvage a specific compound develop a new therapy for a medical need or manage your pipeline more generics companieslooking to move beyond branded and super generics partner with biovista to create value and differentiation through drug repositioning combination therapies novel delivery routes and formulations more patient advocacy groupsthe reality of rare and neglected diseases makes drug repositioning a highly relevant strategy for therapy development . we partner with patient groups to advance therapies using novel cost effective collaboration models more reagent and life sciences product companieshow do you support researchers and make the buying of reagents and life sciences products a more engaging and useful experience biovista s vizit platform shows the way more marketing innovation for reagent and life sciences product companies . biovista on twitter lsn events thanks for the follow oncotargetacd thanks for the follow contribute to arthritis research start w an extensive map of related genes microbiome orgs worldarthritisday https t.co olx3dkwhdq recent posts biovista patent for the use of tetracyclic pyrazinoindoles issued in the eu extreme user profiling good or bad for search and scientific discovery why systematic drug repurposing is here to stay survey of therapeutic strategies for chronic fatigue syndrome biovista inc. announces drug repositioning collaboration with astellas pharma new to drug repositioning read biovista s two contributed chapters in this book or read biovista ceo s interview on the future of drug repositioning follow us contact ususa 2421 ivy road charlottesville va 22903 usa t 1.434.971.1141 f 1.434.971.1144 eu 34 rodopoleos str . ellinikon athens gr 16777 greece t 30.210.9629848 f 30.210.9647606 e info at biovista.com legal sitemap careers 2016 biovista pioneers in systematic drug repositioning all rights reserved .